vs
诺信（NDSN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
诺信的季度营收约是Royalty Pharma plc的1.2倍（$751.8M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 20.2%，领先14.3%），Royalty Pharma plc同比增速更快（4.8% vs 1.0%），过去两年诺信的营收复合增速更高（9.0% vs 4.6%）
诺信（Nordson Corporation）是总部位于美国的跨国企业，专业设计生产民用及工业场景使用的胶粘剂、密封剂、涂料喷涂设备，同时生产电子元器件检测设备、固化及表面处理技术系统，还布局了医疗设备与组件技术相关业务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
NDSN vs RPRX — 直观对比
营收规模更大
NDSN
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出3.8%
1.0%
净利率更高
RPRX
高出14.3%
20.2%
两年增速更快
NDSN
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $751.8M | $622.0M |
| 净利润 | $151.6M | $214.2M |
| 毛利率 | 56.3% | — |
| 营业利润率 | 28.5% | 62.4% |
| 净利率 | 20.2% | 34.4% |
| 营收同比 | 1.0% | 4.8% |
| 净利润同比 | 24.1% | 2.9% |
| 每股收益（稀释后） | $2.67 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NDSNRPRX
| Q4 25 | $751.8M | $622.0M | ||
| Q3 25 | $741.5M | $609.3M | ||
| Q2 25 | $682.9M | $578.7M | ||
| Q1 25 | $615.4M | $568.2M | ||
| Q4 24 | $744.5M | $593.6M | ||
| Q3 24 | $661.6M | $564.7M | ||
| Q2 24 | $650.6M | $537.3M | ||
| Q1 24 | $633.2M | $568.0M |
净利润NDSNRPRX
| Q4 25 | $151.6M | $214.2M | ||
| Q3 25 | $125.8M | $288.2M | ||
| Q2 25 | $112.4M | $30.2M | ||
| Q1 25 | $94.7M | $238.3M | ||
| Q4 24 | $122.2M | $208.2M | ||
| Q3 24 | $117.3M | $544.0M | ||
| Q2 24 | $118.2M | $102.0M | ||
| Q1 24 | $109.6M | $4.8M |
毛利率NDSNRPRX
| Q4 25 | 56.3% | — | ||
| Q3 25 | 54.8% | — | ||
| Q2 25 | 54.7% | — | ||
| Q1 25 | 54.6% | — | ||
| Q4 24 | 54.1% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 56.2% | — | ||
| Q1 24 | 55.0% | — |
营业利润率NDSNRPRX
| Q4 25 | 28.5% | 62.4% | ||
| Q3 25 | 25.3% | 70.1% | ||
| Q2 25 | 24.7% | 36.3% | ||
| Q1 25 | 22.9% | 94.0% | ||
| Q4 24 | 24.0% | 60.9% | ||
| Q3 24 | 25.3% | — | ||
| Q2 24 | 25.9% | 50.2% | ||
| Q1 24 | 25.2% | -13.0% |
净利率NDSNRPRX
| Q4 25 | 20.2% | 34.4% | ||
| Q3 25 | 17.0% | 47.3% | ||
| Q2 25 | 16.5% | 5.2% | ||
| Q1 25 | 15.4% | 41.9% | ||
| Q4 24 | 16.4% | 35.1% | ||
| Q3 24 | 17.7% | 96.3% | ||
| Q2 24 | 18.2% | 19.0% | ||
| Q1 24 | 17.3% | 0.8% |
每股收益（稀释后）NDSNRPRX
| Q4 25 | $2.67 | $0.49 | ||
| Q3 25 | $2.22 | $0.67 | ||
| Q2 25 | $1.97 | $0.07 | ||
| Q1 25 | $1.65 | $0.55 | ||
| Q4 24 | $2.12 | $0.46 | ||
| Q3 24 | $2.04 | $1.21 | ||
| Q2 24 | $2.05 | $0.23 | ||
| Q1 24 | $1.90 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $108.4M | $618.7M |
| 总债务越低越好 | $2.0B | $9.0B |
| 股东权益账面价值 | $3.0B | $9.7B |
| 总资产 | $5.9B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.66× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资NDSNRPRX
| Q4 25 | $108.4M | $618.7M | ||
| Q3 25 | $147.8M | $938.9M | ||
| Q2 25 | $130.2M | $631.9M | ||
| Q1 25 | $130.4M | $1.1B | ||
| Q4 24 | $116.0M | $929.0M | ||
| Q3 24 | $165.3M | $950.1M | ||
| Q2 24 | $125.4M | $1.8B | ||
| Q1 24 | $136.2M | $843.0M |
总债务NDSNRPRX
| Q4 25 | $2.0B | $9.0B | ||
| Q3 25 | $2.1B | $8.9B | ||
| Q2 25 | $2.2B | $8.0B | ||
| Q1 25 | $2.2B | $7.6B | ||
| Q4 24 | $2.2B | $7.6B | ||
| Q3 24 | $1.5B | $7.6B | ||
| Q2 24 | $1.5B | $7.6B | ||
| Q1 24 | $1.6B | $6.1B |
股东权益NDSNRPRX
| Q4 25 | $3.0B | $9.7B | ||
| Q3 25 | $3.0B | $9.6B | ||
| Q2 25 | $3.0B | $9.5B | ||
| Q1 25 | $2.9B | $9.8B | ||
| Q4 24 | $2.9B | $10.3B | ||
| Q3 24 | $2.9B | $10.3B | ||
| Q2 24 | $2.8B | $9.8B | ||
| Q1 24 | $2.7B | $9.9B |
总资产NDSNRPRX
| Q4 25 | $5.9B | $19.6B | ||
| Q3 25 | $6.0B | $19.3B | ||
| Q2 25 | $6.1B | $18.3B | ||
| Q1 25 | $5.9B | $17.6B | ||
| Q4 24 | $6.0B | $18.2B | ||
| Q3 24 | $5.2B | $18.0B | ||
| Q2 24 | $5.2B | $17.7B | ||
| Q1 24 | $5.2B | $16.1B |
负债/权益比NDSNRPRX
| Q4 25 | 0.66× | 0.92× | ||
| Q3 25 | 0.71× | 0.93× | ||
| Q2 25 | 0.74× | 0.84× | ||
| Q1 25 | 0.75× | 0.78× | ||
| Q4 24 | 0.75× | 0.74× | ||
| Q3 24 | 0.52× | 0.74× | ||
| Q2 24 | 0.55× | 0.78× | ||
| Q1 24 | 0.60× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $202.9M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $193.9M | — |
| 自由现金流率自由现金流/营收 | 25.8% | — |
| 资本支出强度资本支出/营收 | 1.2% | — |
| 现金转化率经营现金流/净利润 | 1.34× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $661.1M | — |
8季度趋势，按日历期对齐
经营现金流NDSNRPRX
| Q4 25 | $202.9M | $827.1M | ||
| Q3 25 | $238.0M | $702.6M | ||
| Q2 25 | $119.2M | $364.0M | ||
| Q1 25 | $159.1M | $596.1M | ||
| Q4 24 | $96.4M | $742.5M | ||
| Q3 24 | $164.8M | $703.6M | ||
| Q2 24 | $122.6M | $658.2M | ||
| Q1 24 | $172.4M | $664.6M |
自由现金流NDSNRPRX
| Q4 25 | $193.9M | — | ||
| Q3 25 | $226.4M | — | ||
| Q2 25 | $103.1M | — | ||
| Q1 25 | $137.7M | — | ||
| Q4 24 | $75.8M | — | ||
| Q3 24 | $143.0M | — | ||
| Q2 24 | $108.2M | — | ||
| Q1 24 | $164.8M | — |
自由现金流率NDSNRPRX
| Q4 25 | 25.8% | — | ||
| Q3 25 | 30.5% | — | ||
| Q2 25 | 15.1% | — | ||
| Q1 25 | 22.4% | — | ||
| Q4 24 | 10.2% | — | ||
| Q3 24 | 21.6% | — | ||
| Q2 24 | 16.6% | — | ||
| Q1 24 | 26.0% | — |
资本支出强度NDSNRPRX
| Q4 25 | 1.2% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 2.8% | — | ||
| Q3 24 | 3.3% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 1.2% | — |
现金转化率NDSNRPRX
| Q4 25 | 1.34× | 3.86× | ||
| Q3 25 | 1.89× | 2.44× | ||
| Q2 25 | 1.06× | 12.06× | ||
| Q1 25 | 1.68× | 2.50× | ||
| Q4 24 | 0.79× | 3.57× | ||
| Q3 24 | 1.41× | 1.29× | ||
| Q2 24 | 1.04× | 6.45× | ||
| Q1 24 | 1.57× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NDSN
| Advanced Technology Systems | $624.5M | 83% |
| Other | $127.3M | 17% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
